Yuhan's Reclaza Added to Poland's Reimbursement List...Expansion in European Market

Poland Becomes Second Country After Germany to Cover Reclaza Under National Health Insurance

YuHan Corporation's lung cancer treatment drug, Reclaza (ingredient name: lazertinib), has expanded its list of countries in Europe where it is covered by health insurance. Following Germany, Reclaza has now been added to Poland’s reimbursement list, signaling a full-fledged push into the local first-line therapy market.

Product image of lung cancer treatment drug 'Reclaza'. YuHan Corporation

According to industry sources on March 23, Poland's Ministry of Health announced a new reimbursement drug list effective April 1, 2026, which includes Reclaza among the newly covered medicines. As a result of this announcement, Reclaza will be covered by national insurance starting next month.

The reimbursement applies to first-line treatment for adult patients with non-small cell lung cancer (NSCLC) who have EGFR exon 19 deletion or exon 21 substitution mutations. It also includes combination therapy with Janssen’s bispecific antibody treatment Rybrevant. The regimen involves using the subcutaneous injection Rybrevant (ingredient name: amivantamab) together with Reclaza.

Reclaza previously received marketing authorization from the European Commission (EC). It was first covered by insurance in Germany. With the recent expansion to Poland, the drug is now spreading to other major European countries.

Currently, the European lung cancer treatment market is led by AstraZeneca (AZ)'s Tagrisso (ingredient name: osimertinib). Reclaza is pursuing a strategy to establish a competitive position in the first-line treatment segment by promoting combination therapy.

This content was produced with the assistance of AI translation services.